Xolair

Patients w/ convincing IgE mediated asthma. Add-on therapy to improve asthma control in adult & adolescent (≥12 yr); child (6 to <12 yr) w/ severe persistent allergic asthma who have +ve skin test or in vitro reactivity to perennial aeroallergen, frequent daytime symptoms or night-time awakenings, multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids + long-acting inhaled β₂-agonist; reduced lung function (FEV₁ <80%) (for adult & adolescent only). Add-on therapy to intranasal corticosteroids for chronic rhinosinusitis w/ nasal polyps (CRSwNP) in adult (≥18 yr) w/ inadequate response to intranasal corticosteroids. Add-on therapy for chronic spontaneous urticaria in adult & adolescent (≥12 yr) w/ inadequate response to H₁ antihistamine treatment.

SC Allergic asthma & CRSwNP 75-600 mg in 1-4 inj. Max: 600 mg every 2 wk. Chronic spontaneous urticaria 150-300 mg every 4 wk.

Hypersensitivity.

Antiasthmatic & COPD Preparations

R03DX05 - omalizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.

POM